Denali Therapeutics Inc

NASDAQ:DNLI 4:00:00 PM EDT

16.60

-0.22 (-1.31%)

6:38:08 PM EDT: $16.75 +0.15 (+0.90%)

Market Cap (Intraday)	2.31B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$14.15 Million
Adjusted EPS	-$0.70

See more estimates

10-Day MA	$17.99
50-Day MA	$19.19
200-Day MA	$21.12

See more pivots

Denali Therapeutics Inc Stock, NASDAQ:DNLI

161 Oyster Point Boulevard, 2nd Floor, San Francisco, California 94080

United States of America

Phone: +1.615.866.8548

Number of Employees: 445

http://www.denalitherapeutics.com

Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.